SCHEMBL14009015

SCHEMBL14009015

COc1ccc(NC(=O)c2ccc(C(=O)Nc3ccc(-n4cncn4)cc3)s2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ F10 P00742 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ICAM1 P05362 1/20 0.43
▸ SELE P16581 1/20 0.43
▸ VCAM1 P19320 1/20 0.43
▸ SNCA P37840 1/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ S1PR1 P21453 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14008925 0.89 SMN1; SMN2 (0.54) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL14009249 0.89 RAB9A (0.49) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL14009096 0.89 F10 (0.49) MAPTF10LMNAKDM4ESMN1; SMN2
SCHEMBL14009111 0.89 F10 (0.49) MAPTKMT2AMEN1F10LMNA
SCHEMBL14008991 0.88 CYP1A2 (0.42) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL14009068 0.88 RAB9A (0.44) KMT2AKDM4EICAM1SELEVCAM1
SCHEMBL14009031 0.86 S1PR4 (0.51) MAPTKMT2AMEN1LMNASMN1; SMN2
SCHEMBL14008963 0.86 CYP1A2 (0.47) MAPTKMT2AMEN1LMNARAB9A
SCHEMBL14009309 0.86 RAB9A (0.43) MAPTKMT2AMEN1LMNAKDM4E
SCHEMBL14009071 0.86 MAPT (0.42) MAPTF10LMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
WO-2007022258-A1 NOVEL HIGH AFFINITY THIOPHENE-BASED AND FURAN-BASED KINASE LIGANDS SCHERING CORPORATION (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 MAPT 2145/4885KMT2A 806/4885MEN1 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback